Trials / Completed
CompletedNCT00829374
Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,003 (actual)
- Sponsor
- Medivation, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dimebon | 5 mg orally three times daily |
| DRUG | Dimebon | 20 mg orally three times daily |
| DRUG | Placebo comparator | Placebo orally three times daily |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2009-01-27
- Last updated
- 2016-09-27
Locations
101 sites across 10 countries: United States, Australia, Belgium, Finland, France, Germany, Italy, New Zealand, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00829374. Inclusion in this directory is not an endorsement.